InsidersTradesSigma
Track the 네오팜 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 네오팜 has recorded 6 public disclosures. Market capitalisation: €309.2bn. The latest transaction was disclosed on 8 June 2026 (Purchase). Among the most active insiders: FILLIMITED. The full history is openly available.
6
Insider Decl.
n/a
Thresholds
€8m
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 네오팜 Strong Buy (bullish), based on 1 analysts. Average price target: ₩24,000.
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 1,616 of 29,064 companies
78.3
score / 100
Value69
Quality87
FCF yld7.2%
Earn yld7.4%
EV/EBITDA10.7x
ROE·
Gross mgn65%
Net mgn21%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 June 2026
Declarations6 total
168,460 sharesKRXDART:20260608000105
174,396 sharesKRXDART:20260428000265
195,501 sharesKRXDART:20260401002128
6 of 6 declarations
关于 네오팜
Neopharm 是一家在 XKRX 市场上市的健康和制药公司。它专注于药品和保健产品的开发和销售。